Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors.

Cancer Immunol Res · 2023 · PMC10472109 · PMID 37352396

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, IL2 and IL12 dFab_CCR showed a trend of improved CAR T-cell cytotoxicity ( Fig. 4D ), with dFab_CCR-GMCSF showing significant enhancement.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.